Organoid-based drug Discovery represents an advanced approach for assessing the safety and efficacy of candidate therapeutics. By leveraging engineered, disease-relevant organoid models, this technology enables quantitative evaluation of drug efficacy and toxicity, accelerating drug discovery while reducing reliance on animal studies. It offers a cost- and time-efficient solution with enhanced predictive accuracy, supporting the development of safer, more effective therapies.
Organoid Drug ScreeningOrganoid Drug Screening is a drug screening technology based on patient-derived organoids (PDOs). These models preserve the genomic, phenotypic, and functional features of the original tumors,, providing a more accurate platform for evaluating therapeutic response. Through this platform, we offer efficient and precise drug screening services to accelerate new drug development and evaluate treatment responses across diverse tumor types.
We provide a comprehensive range of drug screening services, includeing small molecule drug screening, enabling identification of promising candidate drugs; antibody-drug conjugate (ADC) screening, to evaluate ADC targets and cytotoxicity; and drug combination screening, assessing synergistic interactions to identify optimal combination regimens.
Drug Sensitivity Testing assesses the sensitivity of specific tumors to different drugs using patient-derived organoid models. This test provides accurate and rapid functional readouts for drug development and preclinical research.
We offer comprehensive drug sensitivity assays to supports individualized treatment decision-making. These include: KRAS mutant drug sensitivity testing, which evaluates the sensitivity of KRAS mutant tumors to specific drugs, and personalized drug screening, tailored to the genetic and phenotypic characteristics of each patient’s tumor.
Organoid Drug Efficacy Services assess the efficacy of candidate drugs using patient-derived tumor organoids, enabling assessment of antitumor activity under physiologically relevant conditions.
We offer organoid- and in vivo–based drug evaluation services: organoid single-agent efficacy testing to quantify dose–response and sensitivity, organoid synergy testing to identify synergistic/antagonistic combinations, indication expansion screening using diverse organoid panels to find new responsive populations, and PDOX/PDX efficacy evaluation to validate antitumor activity and translational potential in patient-derived xenograft models. These services supports verification of the effectiveness therapeutic potential and provides reliable data for preclinical efficacy validation.
Toxicology Screening and Safety EvaluationToxicology Screening and Safety Evaluation examines the toxic effects of candidate drugs on various tissues and organs. Through patient and normal tissue-derived organoid models, we simulate the toxicity responses to evaluate drug safety during preclinical assessment. Services include multi-parameter toxicity assessments such as cell viability loss, apoptosis induction, tissue damage, and metabolic disorders. Both acute and chronic exposure models can be assessed, along with dose–response and time-dependent effects.
We also provide comparative analysis between normal and tumor organoids to determine the therapeutic window and selective toxicity index. Additionally, we offer transcriptomics and proteomics profiling to investigate toxicity-related pathways and molecular targets, supporting early-stage drug optimization.
Organoid-Based Drug Discovery Services content includes but is not limited to：
| Organoid-Based Drug Discovery Services | ||
|---|---|---|
| Organoid Drug Screening | Small Molecule Drug Screening | |
| Large Molecule Drug Screening | ||
| Antibody-drug Conjugate (ADC) Screening | ||
| Drug Sensitivity Testing | KRAS Mutant Drug Sensitivity Testing | |
| KRAS/TP53 Dual-Mutant Drug Sensitivity Testing | ||
| Tumor Organoid–Based Clinical Drug Sensitivity Testing | ||
| Organoid Drug Efficacy Services | Organoid Model Selection & Application Services | |
| Organoid model drug single-agent efficacy test | ||
| Organoid model drug synergistic effect test service | ||
| PDOX/PDX efficacy evaluation | ||
| Toxicology Screening and Safety Evaluation | Drug Toxicology Test | |
Key Advantages:
Broad Drug Coverage: Compatible with large molecules, small molecules, and ADCs across multiple organoid systems.
Personalized and Customizable: Patient-derived organoids (PDOs/PDXOs) support precision medicine and individualized drug validation.
Multi-Parameter Readouts: Allows comprehensive analyses of proliferation, differentiation, molecular markers, inflammation, and toxicity.